Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: A review and update

Clinical and Applied Thrombosis/Hemostasis

Volumn 11, Issue 1, 2005, Pages 1-13

  Bick, Rodger L ^a,b,d   Hoppensteadt, Debra ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Dallas Thromb Hemost/V M C C   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Dalteparin; Heparin; Low molecular weight heparin; Pregnancy; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; CALCIUM; DALTEPARIN; ENOXAPARIN; FOLIC ACID; HEPARIN; HEPARIN COFACTOR II; IRON; LIPOCORTIN 5; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; PREDNISONE; PROTEIN C; PROTEIN S; PYRIDOXINE; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ALLERGIC REACTION; ALOPECIA; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN III DEFICIENCY; BLEEDING; BLEEDING DISORDER; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CAPILLARY RESISTANCE; CHROMOSOME ABERRATION; CONTROLLED STUDY; DELIVERY; ECHOGRAPHY; ERYTHEMA; FEMALE; FEMALE INFERTILITY; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HEMATOMA; HEMOSTASIS; HEPARIN COFACTOR 2 DEFICIENCY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INJECTION SITE; LABOR COMPLICATION; MAJOR CLINICAL STUDY; MATERNAL CARE; METHYLENE TETRAHYDROFOLATE REDUCTASE DEFICIENCY; MTHFR GENE; OSTEOPOROSIS; PAI 1 GENE; PATIENT MONITORING; PATIENT REFERRAL; PHYSICAL EXAMINATION; POSTPARTUM THROMBOSIS; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PRURITUS; RECURRENT ABORTION; RECURRENT MISCARRIAGE SYNDROME; RENDU OSLER WEBER DISEASE; REVIEW; SKIN ALLERGY; SPONTANEOUS ABORTION; STICKY PLATELET SYNDROME; SYNDROME DELINEATION; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR DEFICIENCY; TREATMENT INDICATION; VON WILLEBRAND DISEASE;

ABORTION, HABITUAL; ADULT; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION FACTORS; BLOOD PLATELETS; FEMALE; HUMANS; INFERTILITY, FEMALE; PREGNANCY; THROMBOSIS; TREATMENT OUTCOME;

EID: 13244295538     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960501100101     Document Type: Review

References (82)

1. Bick RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematol Oncol Clin North Am 2000;14:1117.
2. Bick RL, Laughlin HR, Cohen B, et al. Fetal wastage syndrome due to blood protein/platelet defects: Results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin. Clin Appl Thromb Hemost 1995;1:286.
3. Duckert F. The fibrin stabilizing factor, factor XIII. Blut 1973;26:177.
4. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach C, et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Va134Leu polymorphism: Impaired fibrinolysis and early pregnancy loss. Clin Chem 2003;49:1081.
5. Muszbek IA. Coagulation factor deficiencies and pregnancy loss. Sem Thromb Hemost 2003;29:171.
6. Kumar M, Mehta P. Congenital coagulopathies and pregnancy: Report of four pregnancies in a factor X-deficient woman. Am J Hematol 1994;46:241.
7. Valnicek S, Vacl J, Mrazova M, et al. Hemotherapeutic safeguarding of induced abortion in inborn proconvertin insufficiency (hemagglutination factor VII) using exchange plasmapheresis. Zentralbl Gynakol 1972;94:931.
8. Nelson DB, Ness RB, Grisso JA, Cushman M. Influence of hemostatic factors on spontaneous abortion. Am J Perinatol 2001;4:195.
9. Slunsky R. Personal experiences with the antifibrinolytic PAMBA in obstetrics and gynecology. Zentralbl Gynakol 1970;92:364.
10. Owen CA, Henriksen RA, McDuffie FC, Mann KG. Prothrombin quick: A newly identified dysprothrombinemia. Mayo Clin Proceed 1978;53:29.
11. Pauer HU, Burfeind P, Kostering H, et al. Factor XII deficiency is strongly associated with primary recurrent abortions. Fertil Steril 2003;80:590.
12. Jones DW, Gallimore MJ, Winter M. Antibodies to factor XII: A possible predictive marker for recurrent foetal loss. Immunobiology 2003;207:43.
13. Sugi T, Makino T. Antiphospholipid antibodies and kininogens in pathologic pregnancies: A review. Am J Reprod Immunol 2002;47:283.
14. Iinuma Y, Sugiura-Ogasawara M, Makino A, et al. Coagulation factor XII activity, but not an associated common genetic polymorphism (46C/T), is linked to recurrent miscarriage. Fertil Steril 2002;77:353.
15. Yamada H, Kato EH, Ebina Y, et al. Factor XII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest 2000;49:80.
16. Evron S, Anteby SO, Brzezinsky A, et al. Congenital afibrinogenemia and recurrent early abortion. Eur J Obstet Gynecol Reprod Biol 1985;19:307.
17. Mammen EF. Congenital abnormalities of the fibrinogen molecule. Semin Thromb Hemost 1974;1:184.
18. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost 1999;25:333.
19. Bick RL. The antiphospholipid thrombosis syndromes: A common mutlidisciplinary medical problem. Clin Appl Thromb Hemost 1997;3:270.
20. Scott JR, Rote NS, Branch DW. Immunological aspects of recurrent abortion and fetal death. Obstet Gynecol 1987;70:645.
21. Schved JF, Gris JC, Neveu S, et al. Factor XII congenital deficiency and early spontaneous abortion. Fert Steril 1989;52:335.
22. Klein M, Rosen A, Kyrle P, Beck A. Obstetrical management of dysfibrinogenemia with increased thrombophilia. Geburtsh Frauenheilk 1992;52:442.
23. Barkagan ZS, Belykh SI. Protein C deficiency and the multi-thrombotic syndrome associated with pregnancy and abortion. Gematol I Transfuziol 1992;37:35.
24. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: Experience of treatment with heparin and antithrombin. Gynecol Obst Invest 1982;14:127.
25. Simioni P, Lazzaro AR, Coser E, et al. Hereditary heparin cofactor II deficiency and thrombosis: Report of six patients belonging to two separate cohorts. Blood Coag Fibrinol 1990;1:351.
26. Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol 1999;26:1715.
27. Gris J, Neveu S, Mares P, et al. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993;125:606.
28. Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: An independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metab Clin Exp 1999;48:1589.
29. Khamashta MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus 1998;7(Suppl 2):S162.
30. Amengual O, Atsumi T, Khamashta MA, Hughes GR. Advances in antiphospholipid (Hughes') syndrome. Ann Acad Med Singapore 1998;27:61.
31. Bick RL. Antiphospholipid thrombosis syndromes: Etiology, pathophysiology, diagnosis and managment. Int J Hematol 1997;65:193.
32. Bick RL, Baker WF. The antiphospholipid and thrombosis syndromes. Med Clin North Am 1994;78:667.
33. Bick RL, Arun B, Frenkel EP. Antiphospholipid thrombosis syndromes. Haemostasis 1999;29:100.
34. Festin MR, Limson GM, Maruo T. Autoimmune causes of recurrent pregnancy loss. Kobe J Med Sci 1997;43:143.
35. Roussev RG, Kaider BD, Price DE, Coulam CB. Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol (Copenhagen) 1996;35:415.
36. Oshiro BT, Silver RM, Scott JR, et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996;87:489.
37. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509.
38. Borrelli AL, Brillante M, Borzacchiello C, Berlingieri P. Hemocoagulative pathology and immunological recurrent abortion. Clin Exp Obstet Gynecol 1997;24:39.
39. Hellan M, Kuhnel E, Speiser W, et al. Familial lupus anticoagulant: A case report and review of the literature. Blood Coagul Fibrinol 1998;9:195.
40. Ogasawara M, Aoki K, Matsuura E, et al. Anti beta-2-glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: Prevalence and clinical significance. Lupus 1996;5:587.
41. Zangari M, Lockwood CJ, Scher J, Rand JH. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Thromb Res 1997;85:177.
42. Aznar J. Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. Haematologica 1999;84:80.
43. Aznar J, Villa P, Espana F, et al. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med 1997;130:202.
44. Schultz DR. Antiphospholipid antibodies: Basic immunology and assays. Semin Arth Rheum 1997;26:724.
45. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998;79:276.
46. Martini A, Ravelli A. The clinical significance of antiphospholipid antibodies. Ann Med 1997;29:159.
47. Bussen SS, Steck T. Thyroid antibodies and their relation to antithrombin antibodies, anticardiolipin antibodies and lupus anticoagulant in women with recurrent spontaneous abortions (antithyroid, anticardiolipin and antithrombin autoantibodies and lupus anticoagulant in habitual aborters). Eur J Obstet Gynecol Reprod Biol 1997;74:139.
48. Rand JH, Wu XX. Antibody-mediated disruption of the annexin-V antithrombotic shield: A new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost 1999;82:649.
49. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: A "lupus procoagulant" phenomenon. Blood 1998;92:1652.
50. Rauch J. Lupus anticoagulant antibodies: Recognition of phospholipid-binding protein complexes. Lupus 1998;7 (Suppl 2):S29.
51. Rote NS, Vogt E, DeVere G, et al. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol (Copenhagen) 1998;39:125.
52. Vogt E, Ng AK, Rote NS. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol. 1997;177:964.
53. Lakasing L, Campa JS, Poston R, et al. Normal expression of tissue factor, thrombomodulin, and annexin V in placentas from women with antiphospholipid syndrome. Am J Obstet Gynecol 1999;181:180.
54. Siaka C, Lambert M, Caron C, et al. Low prevalence of anti-annexin V antibodies in antiphospholipid syndrome with fetal loss. Rev Med Intern 1999;20:762.
55. Kaburaki J, Kuwana M, Yamamoto M, et al. Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus. Am J Hematol 1997;54:209.
56. Eschwege V, Peynaud-Debayle E, Wolf M, et al. Prevalence of antiphospholipid-related antibodies in unselected patients with history of venous thrombosis. Blood Coagul Fibrinol 1998;9:429.
57. Silver RM, Pierangeli SS, Edwin SS, et al. Pathogenic antibodies in women with obstetric features of antiphospholipid syndrome who have negative test results for lupus anticoagulant and anticardiolipin antibodies. Am J Obstet Gynecol 1997;176:628.
58. Branch DW, Silver R, Pierangeli S, et al. Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997;89:549.
59. Gris JC, Ripart-Neveu S, Maugard C, et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997;77:1096.
60. Tal J, Schliamser LM, Leibovitz Z, et al. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod 1999;14:1624.
61. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1998;71:1048.
62. Dhalback B. Activated protein C resistence and thrombosis: Molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999;25:273.
63. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997;97:551.
64. Bokarewa MI, Bremme K, Blomback M. Arg 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996;92:473.
65. Rai R, Regan L, Hadley E, et al. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol 1996;92:489.
66. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden mutation is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822.
67. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998;128:1000.
68. Poort S, Rosendaal F, Reitsma P, Bertina R. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698.
69. Brenner B, Sarig G, Weiner Z, et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999;82:6.
70. Toschi V, Motta A, Costelli C, et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759.
71. Sher G, Feinman M, Zouves C, et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994;9:2278.
72. Rosove MH, Tabsh K, Wasserstrum N, et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 1990;75:630.
73. Brown HL. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol 1991;34:17.
74. Perino A, Barba G, Cimino C, et al. Immunological problems in the recurrent abortion syndrome. Acta Eur Fertil 1989;20:199.
75. Many A, Pauzner R, Carp H, et al. Treatment of patients with antiphospholipid antibodies during pregnancy. Am J Reprod Immunol 1992;28:216.
76. Lubbe WF, Liggins GC. Role of lupus anticoagulant and autoimmunity in recurrent fetal loss. Semin Reprod Endocrinol 1988;6:181.
77. Lin Q. Investigation of the association between autoantibodies and recurrent abortions. Chin J Obstet Gynecol 1993;28:674.
78. Cowchuck FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol 1992;166:1318.
79. Landy HJ, Kessler C, Kelly WK, Weingold AB. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies. Am J Perinatol 1992;9:146.
80. Semprini AE, Vucetich A, Garbo S, et al. Effect of prednisone and heparin treatment in 14 patients with poor reproductive efficiency related to lupus anticoagulant. Fetal Ther 1989;4(Suppl 1):73.
81. Kutteh WH. Heparin plus aspirin (Hep + ASA) is superior to aspirin alone (ASA) for the treatment of recurrent pregnancy loss (RPL) associated with antiphospholipid antibodies (APA). Proceedings: American College of Obsetricians and Gynecologists, 1994 (abstract).
82. Parke A. The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. In Ballow M (ed): IVIG Therapy Today. Totowa NJ: Humana, 1992:105.